{"product_id":"nanocarrier-vaccines-biopharmaceutics-based-fast-track-development-hardback-9781394174683","title":"Nanocarrier Vaccines; Biopharmaceutics-Based Fast Track Development (Hardback) 9781394174683","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eNanocarrier Vaccines\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003eBiopharmaceutics-Based Fast Track Development\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eVivek P. Chavda (Edited by), Chavda (Author), Vasso Apostolopoulos (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781394174683, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 5 March 2024\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e528 pages\u003cbr\u003e22.9 x 15.2 x 3.1 cm, 1.025 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cb\u003eNANOCARRIER VACCINES\u003c\/b\u003e \u003cp\u003e \u003cb\u003eThis book details the benefits, restrictions, and types of nanoparticles used in the creation of vaccines for the treatment and prevention of illnesses.\u003c\/b\u003e \u003c\/p\u003e\n\u003cp\u003eIn nanomedicine and nano-delivery systems, materials in the nanoscale range are used as diagnostic instruments or to administer therapeutic compounds to particular targeted regions in a controlled manner. By delivering precise medications to specified locations and targets, nanotechnology provides several advantages in treating chronic human illnesses. The use of nanomedicine (including chemotherapeutic medicines, biological agents, immunotherapeutic agents, etc.) in the treatment of various diseases has recently seen many notable applications. This book aims to be a single source material for understanding all the current and novel advancements in the field of nanotechnology.  \u003c\/p\u003e\n\u003cp\u003eIn this groundbreaking book the reader will find: \u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ebiodegradable and non-biodegradable formulations and properties such as size, shape, charge, inertness, efficacy, morphology, and more;\u003c\/li\u003e \u003cli\u003eshow how different nanoparticles, such as lipid-based, viral vector-based, and metal, uphold very significant properties individually, suggesting applicability in various management tactics;\u003c\/li\u003e \u003cli\u003eexamines how genetic information-carrying entities are becoming the norm for eradicating some diseases; \u003c\/li\u003e \u003cli\u003egathers an exhaustive amount of information on routes of administration such as the oral route, mucosal immunity, intramuscular, subcutaneous, and intradermal; \u003c\/li\u003e \u003cli\u003eexplores the legal regulations for nanotechnology-based approaches.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003e\u003cb\u003eAudience\u003c\/b\u003e \u003c\/p\u003e\n\u003cp\u003eResearchers and pharmacy students in biomedical engineering and chemical engineering, biotechnology, as well as pharmaceutical and biopharmaceutical industry engineers working in drug discovery, chemical biology, computational chemistry, medicinal chemistry, and bioinformatics.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003ePreface xxi\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 General 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 History of Nanoparticles 3\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eKeshava L. Jetha, Arya Vyas, Divya Teli, Amit Chaudhari, Riyansi Satasiya, Vishwa Patel, Shailvi Soni, Shail Modi and Vasso Apostolopoulos\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 4\u003c\/p\u003e \u003cp\u003e1.2 History of Nanoparticles 5\u003c\/p\u003e \u003cp\u003e1.3 Modern Development of Nanoparticles 8\u003c\/p\u003e \u003cp\u003e1.4 Type of Nanoparticles 10\u003c\/p\u003e \u003cp\u003e1.5 Properties of Nanoparticles 13\u003c\/p\u003e \u003cp\u003e1.6 Importance of Nanoparticles 15\u003c\/p\u003e \u003cp\u003e1.7 Conclusion and Future Prospect 18\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Composition of Nanoparticles 25\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eAmit Chaudhari, Palak Vadodariya, Arya Vyas, Disha Patel and Divya Teli\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 25\u003c\/p\u003e \u003cp\u003e2.2 Types of Nanoparticles 27\u003c\/p\u003e \u003cp\u003e2.3 Composition of Nanoparticles 40\u003c\/p\u003e \u003cp\u003e2.4 Synthesis of Nanoparticles 45\u003c\/p\u003e \u003cp\u003e2.5 Nanoparticle Characterization by Various Instrumental Techniques 50\u003c\/p\u003e \u003cp\u003e2.6 Understanding Nanotoxicity: Potential Risks and Implications 53\u003c\/p\u003e \u003cp\u003e2.7 Conclusion 54\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Nanotechnology and Vaccine Development 63\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eKeshava L. Jetha, Praful D. Bharadia and Manish P. Patel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 63\u003c\/p\u003e \u003cp\u003e3.2 Overview of Vaccine Development 64\u003c\/p\u003e \u003cp\u003e3.3 Advantages of Nanoparticles in Vaccine Delivery 66\u003c\/p\u003e \u003cp\u003e3.4 Types of Nanoparticles as Vaccine Carriers 67\u003c\/p\u003e \u003cp\u003e3.5 Development of Nanoparticle-Based Vaccine 70\u003c\/p\u003e \u003cp\u003e3.6 Adjuvants and their Role in Vaccine Development 72\u003c\/p\u003e \u003cp\u003e3.7 Nanoscale Adjuvants 74\u003c\/p\u003e \u003cp\u003e3.8 Advantages 75\u003c\/p\u003e \u003cp\u003e3.9 Techniques for Nanoscale Adjuvants 76\u003c\/p\u003e \u003cp\u003e3.10 Route of Administration for Vaccines 77\u003c\/p\u003e \u003cp\u003e3.11 Recent Advances in Nanotechnology-Based Vaccines 79\u003c\/p\u003e \u003cp\u003e3.12 The Regulatory Perspective of Nanoparticle-Based Vaccine Development 80\u003c\/p\u003e \u003cp\u003e3.13 Future Prospects 81\u003c\/p\u003e \u003cp\u003e3.14 Conclusion 84\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Nanoparticle Formulations: A Sustainable Approach to Biodegradable and Non-Biodegradable Products 95\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eAmandeep Singh, Shreni Parikh, Nutan Sethi, Sachin Patel, Nrupal Modi and Kaushika Patel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 96\u003c\/p\u003e \u003cp\u003e4.2 Types of Nanoparticles 96\u003c\/p\u003e \u003cp\u003e4.3 Preparation of Nanoparticles 100\u003c\/p\u003e \u003cp\u003e4.4 Factors Affecting Selection of Method 100\u003c\/p\u003e \u003cp\u003e4.5 Polymers Used in NP Formulation 107\u003c\/p\u003e \u003cp\u003e4.6 Nanoparticle Formulations Based on Biodegradable Polymers 107\u003c\/p\u003e \u003cp\u003e4.7 Nanoparticle Formulations Based on Non-Biodegradable Polymers 115\u003c\/p\u003e \u003cp\u003e4.8 Nanoparticle Formulations Based on Natural Polymers 118\u003c\/p\u003e \u003cp\u003e4.9 Challenges in NPs from Laboratory to Industrial Scale-Up 121\u003c\/p\u003e \u003cp\u003e4.10 Nanoparticle-Based Approved \u0026amp; Marketed Formulations 122\u003c\/p\u003e \u003cp\u003e4.11 Future Aspects \u0026amp; Conclusion 122\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Nanoparticle Properties: Size, Shape, Charge, Inertness, Efficacy, Morphology 153\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eKajal P. Baviskar, Brijesh M. Shah, Anjali P. Bedse, Shilpa S. Raut, Suchita P. Dhamane and Dhara J. Dave\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 154\u003c\/p\u003e \u003cp\u003e5.2 Applications of Nanoparticle Formulations 155\u003c\/p\u003e \u003cp\u003e5.3 Interaction with Cells 157\u003c\/p\u003e \u003cp\u003e5.4 Properties of Nanoparticles 159\u003c\/p\u003e \u003cp\u003e5.5 Role of Physicochemical Properties in Nanoparticle Toxicity 174\u003c\/p\u003e \u003cp\u003e5.6 Conclusion 177\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Nanoparticles to Deliver Antigen 193\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Viral Vector–Based Nanoparticles 195\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eSuneetha Vuppu, Vivek P. Chavda, Toshika Mishra, Oishani Sengupta, Anand Sairam, Paridhi Soni, Mohit Joshi, Bhumi Bhalodiya and Raj V.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 196\u003c\/p\u003e \u003cp\u003e6.2 Characteristics of Viral Vector–Based Nanoparticles 197\u003c\/p\u003e \u003cp\u003e6.3 Applications 199\u003c\/p\u003e \u003cp\u003e6.4 Novel Advancements in Applications of Viral Nanoparticles 225\u003c\/p\u003e \u003cp\u003e6.5 Limitations and Prospects of Viral Vector–Based Nanoparticle Approach 233\u003c\/p\u003e \u003cp\u003e6.6 Conclusion 234\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Lipid-Based Nanoparticles 241\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eSunny Shah, Hardik Madhu, Moinuddin Soniwala, Dhaval Mori, Amit Vyas, Advaita Chauhan and Bhupendra Prajapati\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 242\u003c\/p\u003e \u003cp\u003e7.2 Types of Lipid-Based Nanoparticles 243\u003c\/p\u003e \u003cp\u003e7.3 Synthesis of Lipid-Based Nanoparticles 245\u003c\/p\u003e \u003cp\u003e7.4 Characterization of Lipid Nanoparticles 251\u003c\/p\u003e \u003cp\u003e7.5 Applications of Lipid-Based Nanoparticles in Vaccines 257\u003c\/p\u003e \u003cp\u003e7.6 Challenges and Future Directions 261\u003c\/p\u003e \u003cp\u003e7.7 Conclusion 267\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Nanoparticle-Based mRNA Vaccines: Are We One Step Closer to Targeted Cancer Therapy? 275\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eLakshmi Vineela Nalla, Siva Nageswararao Gajula and Vivek P. Chavda\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 276\u003c\/p\u003e \u003cp\u003e8.2 Use of mRNA in Vaccines: Advantages and Challenges 278\u003c\/p\u003e \u003cp\u003e8.3 How Do mRNA Vaccines Work? 279\u003c\/p\u003e \u003cp\u003e8.4 Nanocarriers for mRNA Delivery 281\u003c\/p\u003e \u003cp\u003e8.5 Nanoparticle-Based mRNA Vaccines in Cancer Therapy 285\u003c\/p\u003e \u003cp\u003e8.6 Clinical Trials 291\u003c\/p\u003e \u003cp\u003e8.7 Conclusion 295\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Protein Delivery by Nanoparticles 305\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eHarshita Gauraha, Ankita Bhadoriya, Rupesh K. Gautam and Dinesh Kumar Mishra\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 305\u003c\/p\u003e \u003cp\u003e9.2 Major Challenges in Protein Delivery 307\u003c\/p\u003e \u003cp\u003e9.3 Nanotechnology 308\u003c\/p\u003e \u003cp\u003e9.4 Nanoparticles 310\u003c\/p\u003e \u003cp\u003e9.5 Methods of Preparation 317\u003c\/p\u003e \u003cp\u003e9.6 Nanoformulations Available for Protein and Peptide Delivery 322\u003c\/p\u003e \u003cp\u003e9.7 Clinical Trials and Market-Approved Nanoparticles 325\u003c\/p\u003e \u003cp\u003e9.8 Characterization of Protein Nanoparticles 329\u003c\/p\u003e \u003cp\u003e9.9 Applications of Protein Nanoparticles 331\u003c\/p\u003e \u003cp\u003e9.10 Conclusion 336\u003c\/p\u003e \u003cp\u003e9.11 Future Developments 337\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Route of Administration 345\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Oral Vaccine Delivery: Current Status 347\u003c\/b\u003e\u003cbr\u003e\u003ci\u003ePankti C. Balar, Vidhi A. Modh, Sanjay P. Chauhan, Hetvi K. Solanki, Rajeshkumar K. Patel, Dasharath M. Patel and Maharshi B. Padya\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 348\u003c\/p\u003e \u003cp\u003e10.2 Need for Oral Vaccines 349\u003c\/p\u003e \u003cp\u003e10.3 Nanoparticles as an Oral Vaccine Delivery System 350\u003c\/p\u003e \u003cp\u003e10.4 Advantages of Oral Nanovaccines 355\u003c\/p\u003e \u003cp\u003e10.5 Drawbacks and Disadvantages of Oral Nanovaccines 355\u003c\/p\u003e \u003cp\u003e10.6 Barriers in Oral Vaccines Delivery 356\u003c\/p\u003e \u003cp\u003e10.7 Currently Licensed Oral Vaccines 357\u003c\/p\u003e \u003cp\u003e10.8 Descriptions of Licensed Oral Vaccines 360\u003c\/p\u003e \u003cp\u003e10.9 Conclusion and Future Prospect 361\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Nanovaccines for Mucosal Immunity 367\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eShashi Kiran Misra, Anupria Kapoor and Kamla Pathak\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 368\u003c\/p\u003e \u003cp\u003e11.2 Mucosal Immunity 372\u003c\/p\u003e \u003cp\u003e11.3 Nanovaccine Formulations 375\u003c\/p\u003e \u003cp\u003e11.4 Future Perspectives 393\u003c\/p\u003e \u003cp\u003e11.5 Conclusion 396\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Nanovaccine via Intramuscular, Subcutaneous, and Intradermal Routes 405\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eDixa A. Vaghela, Maharshi Bhailalbhai Pandya, Pooja M. Parmar, Sanjay P. Chauhan, Akta Vaishnav, Rajeshkumar K. Patel, Dasharath M. Patel, Vidhi Ankit Modh and Mihir K. Raval\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 406\u003c\/p\u003e \u003cp\u003e12.3 Introduction to the Route of Administration 409\u003c\/p\u003e \u003cp\u003e12.4 Comparable Adaptive Immune Response After IM, SC, and ID Routes 415\u003c\/p\u003e \u003cp\u003e12.5 Marketed Formulation 416\u003c\/p\u003e \u003cp\u003e12.6 Challenges of Vaccine Delivery 417\u003c\/p\u003e \u003cp\u003e12.7 Conclusion 418\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4 Application and Advances 423\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Nanovaccines for Veterinary Applications 425\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eSuneetha Vuppu, Vivek P. Chavda, Toshika Mishra, Swati Punetha, Nikita Sharma, Sathvika Kamaraj and Raj V.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 426\u003c\/p\u003e \u003cp\u003e13.2 Nanovaccines and Immune Response 431\u003c\/p\u003e \u003cp\u003e13.3 Vaccine Production 433\u003c\/p\u003e \u003cp\u003e13.4 Veterinary Applications of Nanovaccines 435\u003c\/p\u003e \u003cp\u003e13.5 Comparative Analysis of Animal Vaccines, Nanovaccines, and Edible Vaccines 439\u003c\/p\u003e \u003cp\u003e13.6 Regulation of Vaccine Production Process 441\u003c\/p\u003e \u003cp\u003e13.7 New Approaches 450\u003c\/p\u003e \u003cp\u003e13.8 Applications of Different Polymer-Based Nanoparticles 451\u003c\/p\u003e \u003cp\u003e13.9 Future Prospects 453\u003c\/p\u003e \u003cp\u003e13.10 Conclusion 454\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Regulatory Pathways for Nanocarrier Vaccine 465\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eNiva Rani Gogoi, Rajashri Bezbaruah, Vishwa Patel, Riyansi Satasia, Bedanta Bhattacharjee and Bhaskar Mazumder\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 466\u003c\/p\u003e \u003cp\u003e14.2 The Need for a Regulatory Framework 467\u003c\/p\u003e \u003cp\u003e14.3 Regulatory Requirements for the Manufacturing of NVs 469\u003c\/p\u003e \u003cp\u003e14.4 Clinically Approved Nanocarrier Vaccines 470\u003c\/p\u003e \u003cp\u003e14.5 Regulatory Challenges 474\u003c\/p\u003e \u003cp\u003e14.6 Global Strategies for Clinical Approval 476\u003c\/p\u003e \u003cp\u003e14.7 Conclusion and Future Prospects 479\u003c\/p\u003e \u003cp\u003eReferences 479\u003c\/p\u003e \u003cp\u003eIndex 487\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Chemistry [\u003ca title=\"See our other books on Chemistry\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Chemistry%20%5BPN%5D%22\"\u003ePN\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley-Scrivener","offers":[{"title":"Brand New","offer_id":52431056175384,"sku":"9781394174683","price":158.29,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9781394174683.jpg?v=1784770153","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/nanocarrier-vaccines-biopharmaceutics-based-fast-track-development-hardback-9781394174683","provider":"Freshly Printed Books","version":"1.0","type":"link"}